P874: LONG-TERM REMISSION AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AFTER TREATMENT OF LCAR-B38M CAR-T – AT LEAST 5-YEAR FOLLOW-UP IN LEGEND-2

• Jian‑qing MI,
• Wan‑hong Zhao,
• Li‑juan Chen,
• Weijun Fu,
• Bai‑yan Wang,
• Jie Xu,
• Jie Liu,
• Shi‑wei Jin,
• Han Zhu,
• Juan Du,
• Hua Jiang,
• Huabin Sun,
• Yehui Jia,
• Xiao‑hu Fan,
• Jian‑yong LI,
• Jian Hou,
• Zhu Chen,
• Wang‑gang Zhang,
• Ai‑li He,
• Sai‑juan Chen

Affiliations

Jian‑qing MI

1 State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China

Wan‑hong Zhao

2 Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Li‑juan Chen

3 Department of Hematology, Jiangsu Province Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Weijun Fu

4 Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, China and Department of Hematology, School of Medicine, Shanghai Fourth People’s Hospital, Tongji University, Shanghai, China

Bai‑yan Wang

2 Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Jie Xu

1 State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China

Jie Liu

2 Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Shi‑wei Jin

1 State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China

Han Zhu

3 Department of Hematology, Jiangsu Province Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Juan Du

5 Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, China

Hua Jiang

5 Department of Hematology, Changzheng Hospital, The Second Military Medical University, Shanghai, China

Huabin Sun

6 Janssen China Research & Development, Raritan, NJ, USA

Yehui Jia

7 Nanjing Legend Biotech Inc., Nanjing, China

Xiao‑hu Fan

7 Nanjing Legend Biotech Inc., Nanjing, China

Jian‑yong LI

3 Department of Hematology, Jiangsu Province Hospital, First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Jian Hou

8 Department of Hematology, Renji Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China

Zhu Chen

1 State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China

Wang‑gang Zhang

2 Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Ai‑li He

2 Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

Sai‑juan Chen

1 State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine, Shanghai Institute of Hematology, Ruijin Hospital Affiliated With Shanghai Jiao Tong University School of Medicine, Shanghai, China